Sinocelltech Ltd.
Clinical trials sponsored by Sinocelltech Ltd., explained in plain language.
-
New hope for lung cancer: experimental drug combo enters trial
Disease control Not yet recruitingThis study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will…
Phase: PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
New hope for lymphoma patients: experimental combo targets hard-to-treat cancer
Disease control Not yet recruitingThis study tests whether a new drug called SCTB35, when combined with lenalidomide, works better than the standard combination of rituximab and lenalidomide for people with follicular lymphoma that has returned or not responded to prior therapy. About 93 adults aged 18-80 will ta…
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests two experimental drugs (SCTB41 and SCTB39-1) given together, sometimes with standard cancer therapy, in adults with advanced solid tumors that have not responded to prior treatments. The goal is to find safe doses and see if the combination can shrink tumors or s…
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC
-
New lupus drug trial aims to tame the immune system
Disease control Not yet recruitingThis study tests a new medicine, SCTC21C, in 159 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if the drug is safe and can reduce lupus symptoms. Participants must be on stable standard treatments and will receive the study drug …
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Not yet recruitingThis study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC